Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
Total Valuation
Black Diamond Therapeutics has a market cap or net worth of $144.72M. The enterprise value is $99.93M.
Market Cap$144.72M
Enterprise Value$99.93M
Share Statistics
Black Diamond Therapeutics has 56,974,915 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding56,974,915
Owned by Insiders13.86%
Owned by Institutions36.25%
Financial Efficiency
Black Diamond Therapeutics’s return on equity (ROE) is -0.84 and return on invested capital (ROIC) is -74.69%.
Return on Equity (ROE)-0.84
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-74.69%
Return on Capital Employed (ROCE)-0.77
Revenue Per Employee0.00
Profits Per Employee-2.90M
Employee Count24
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Black Diamond Therapeutics is 7.2. Black Diamond Therapeutics’s PEG ratio is 0.05.
PE Ratio7.2
PS Ratio0.00
PB Ratio1.41
Price to Fair Value1.41
Price to FCF-1.89
Price to Operating Cash Flow12.34
PEG Ratio0.05
Income Statement
In the last 12 months, Black Diamond Therapeutics had revenue of 0.00 and earned -69.68M in profits. Earnings per share was -1.27.
Revenue0.00
Gross Profit0.00
Operating Income-78.78M
Pretax Income-69.68M
Net Income-69.68M
EBITDA-78.44M
Earnings Per Share (EPS)-1.27
Cash Flow
In the last 12 months, operating cash flow was 21.35M and capital expenditures 0.00, giving a free cash flow of 21.35M billion.
Operating Cash Flow21.35M
Free Cash Flow21.35M
Free Cash Flow per Share0.37
Dividends & Yields
Black Diamond Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.07
52-Week Price Change18.72%
50-Day Moving Average3.60
200-Day Moving Average2.73
Relative Strength Index (RSI)31.04
Average Volume (3m)1.54M
Important Dates
Black Diamond Therapeutics upcoming earnings date is Mar 18, 2026, Before Open (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 18, 2026
Ex-Dividend Date―
Financial Position
Black Diamond Therapeutics as a current ratio of 4.92, with Debt / Equity ratio of 12.71%
Current Ratio4.92
Quick Ratio4.92
Debt to Market Cap0.00
Net Debt to EBITDA0.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Black Diamond Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Black Diamond Therapeutics EV to EBITDA ratio is -1.49, with an EV/FCF ratio of -1.66.
EV to Sales0.00
EV to EBITDA-1.49
EV to Free Cash Flow-1.66
EV to Operating Cash Flow-1.66
Balance Sheet
Black Diamond Therapeutics has $135.50M in cash and marketable securities with $16.04M in debt, giving a net cash position of $119.47M billion.
Cash & Marketable Securities$135.50M
Total Debt$16.04M
Net Cash$119.47M
Net Cash Per Share$2.10
Tangible Book Value Per Share$1.51
Margins
Gross margin is 99.51%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin99.51%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Black Diamond Therapeutics is $8.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.25
Price Target Upside224.80% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―